Bexarotene - Latest Advances

Decoding the Effects of Bexarotene treatment on brain of AD-like model mice: Single-Cell Transcriptomics and Chromatin Accessibility Analysis.

Journal: Research square

Published: August 20, 2025

A bexarotene-attached Re(I) tricarbonyl complex for NADH oxidation and ROS-mediated cancer phototherapy.

Journal: Chemical communications (Cambridge, England)

Published: August 07, 2025

Brain single-cell transcriptional responses to bexarotene-activated RXR in Alzheimer's disease model.

Journal: bioRxiv : the preprint server for biology

Published: August 06, 2025

Prognostic significance of APOBEC1 and its role in lung squamous cell carcinoma: insights from chromatin regulator-based modeling and experimental validation.

Journal: Expert review of anticancer therapy

Published: August 05, 2025

Serum neurofilament light chain levels suggest neuroprotection following bexarotene-induced remyelination in people with relapsing remitting multiple sclerosis.

Journal: Multiple sclerosis and related disorders

Published: July 25, 2025

Development of an RXR Agonist Scaffold with Pronounced Homodimer Preference.

Journal: Journal of medicinal chemistry

Published: July 24, 2025

TRIC Coupled with TR-FRET as a High-Throughput Screening Platform for the Discovery of SLIT2 Binders: A Proof-of-Concept Approach.

Journal: bioRxiv : the preprint server for biology

Published: July 17, 2025

An Open-Label, Multicenter, Phase II Study of Bexarotene in Patients With Adult T-Cell Leukemia/Lymphoma.

Journal: The Journal of dermatology

Published: July 12, 2025

Orthogonal temperature-related intensity change (TRIC) and TR-FRET as a high-throughput screening platform for the discovery of SLIT2 binders: A proof-of-concept approach.

Journal: SLAS discovery : advancing life sciences R & D

Published: July 01, 2025

Selecting appropriate therapy for cutaneous T-cell lymphomas (CTCLs): recent advances and the unmet need.

Journal: Expert opinion on pharmacotherapy

Published: May 08, 2025

Dual Anti-inflammatory Actions of a Novel Retinoid X Receptor Agonist Derived from a Natural Compound in Microglial Cells.

Journal: Biological & pharmaceutical bulletin

Published: April 23, 2025

RXR agonist S169 inhibits HBV/HDV entry in vitro by disrupting KIF4-dependent NTCP trafficking.

Journal: Antiviral research

Published: April 21, 2025

Filters

Decoding the Effects of Bexarotene treatment on brain of AD-like model mice: Single-Cell Transcriptomics and Chromatin Accessibility Analysis.

Decoding the Effects of Bexarotene treatment on brain of AD-like model mice: Single-Cell Transcriptomics and Chromatin Accessibility Analysis.

A bexarotene-attached Re(I) tricarbonyl complex for NADH oxidation and ROS-mediated cancer phototherapy.

A bexarotene-attached Re(I) tricarbonyl complex for NADH oxidation and ROS-mediated cancer phototherapy.

Brain single-cell transcriptional responses to bexarotene-activated RXR in Alzheimer's disease model.

Brain single-cell transcriptional responses to bexarotene-activated RXR in Alzheimer's disease model.

Prognostic significance of APOBEC1 and its role in lung squamous cell carcinoma: insights from chromatin regulator-based modeling and experimental validation.

Prognostic significance of APOBEC1 and its role in lung squamous cell carcinoma: insights from chromatin regulator-based modeling and experimental validation.

Serum neurofilament light chain levels suggest neuroprotection following bexarotene-induced remyelination in people with relapsing remitting multiple sclerosis.

Serum neurofilament light chain levels suggest neuroprotection following bexarotene-induced remyelination in people with relapsing remitting multiple sclerosis.

Development of an RXR Agonist Scaffold with Pronounced Homodimer Preference.

Development of an RXR Agonist Scaffold with Pronounced Homodimer Preference.

TRIC Coupled with TR-FRET as a High-Throughput Screening Platform for the Discovery of SLIT2 Binders: A Proof-of-Concept Approach.

TRIC Coupled with TR-FRET as a High-Throughput Screening Platform for the Discovery of SLIT2 Binders: A Proof-of-Concept Approach.

An Open-Label, Multicenter, Phase II Study of Bexarotene in Patients With Adult T-Cell Leukemia/Lymphoma.

An Open-Label, Multicenter, Phase II Study of Bexarotene in Patients With Adult T-Cell Leukemia/Lymphoma.

Orthogonal temperature-related intensity change (TRIC) and TR-FRET as a high-throughput screening platform for the discovery of SLIT2 binders: A proof-of-concept approach.

Orthogonal temperature-related intensity change (TRIC) and TR-FRET as a high-throughput screening platform for the discovery of SLIT2 binders: A proof-of-concept approach.

Selecting appropriate therapy for cutaneous T-cell lymphomas (CTCLs): recent advances and the unmet need.

Selecting appropriate therapy for cutaneous T-cell lymphomas (CTCLs): recent advances and the unmet need.

Dual Anti-inflammatory Actions of a Novel Retinoid X Receptor Agonist Derived from a Natural Compound in Microglial Cells.

Dual Anti-inflammatory Actions of a Novel Retinoid X Receptor Agonist Derived from a Natural Compound in Microglial Cells.

RXR agonist S169 inhibits HBV/HDV entry in vitro by disrupting KIF4-dependent NTCP trafficking.

RXR agonist S169 inhibits HBV/HDV entry in vitro by disrupting KIF4-dependent NTCP trafficking.